Survival Outcomes after Placement of Inferior Vena Cava Filters in Cancer Patients: Insights from a Comprehensive Cancer Center’s Experience

Background: Inferior vena cava (IVC) filters serve as a vital intervention when systemic anticoagulation proves ineffective or contraindicated, particularly in the context of cancer patients. This study aimed to provide real-world insights into the outcomes of cancer patients following IVC filter placement. Patients and methods: Cancer patients with IVC filters were retrospectively reviewed. The indications and survival outcomes following IVC filter insertion have been reported. Results: A total of 176 cancer patients with IVC filters were included in the study. The median patient age was 56 years (range: 18–88 years). Solid tumors were the most common primary cancers (n = 125, 71.0%), and the majority (n = 99, 79.2%) had the advanced-stage disease at the time of IVC insertion. The filters were inserted because of contraindications to anticoagulation (n = 99, 56.3%) or the failure of anticoagulation (n = 56, 31.8%). The median survival (range) following filter placement was only 2 (1.45–2.55) months for patients with advanced-stage solid tumors, 5 (0.62–9.38) months for patients with brain tumors, and 44 (8.59–79.41) months for those with early-stage solid tumors, p < 0.001. Conclusions: Our findings suggest that IVC filter placement offers limited benefits to patients with advanced-stage disease. The underlying tumor, stage, and life expectancy are crucial factors in the decision-making process before IVC filter insertion.

[1]  K. Nasserinejad,et al.  The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis , 2023, EClinicalMedicine.

[2]  V. Gorantla,et al.  Inferior Vena Cava Filters and Complications: A Systematic Review , 2023, Cureus.

[3]  F. Klok,et al.  Long-Term Prognostic Impact of Pulmonary Hypertension After Venous Thromboembolism. , 2023, The American journal of cardiology.

[4]  A. Fentie,et al.  Incidence and Determinants of Chemotherapy Associated Thromboembolic Events among Ethiopian Patients Treated for Solid Malignancy: A Retrospective Cross-Sectional Study , 2022, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[5]  Rongchang Chen,et al.  Effect of inferior vena cava filters on pulmonary embolism-related mortality and major complications: a systematic review and meta-analysis of randomized controlled trials. , 2021, Journal of vascular surgery. Venous and lymphatic disorders.

[6]  S. Partovi,et al.  Inferior vena cava filter - comprehensive overview of current indications, techniques, complications and retrieval rates. , 2020, VASA. Zeitschrift fur Gefasskrankheiten.

[7]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[8]  D. Ghosh,et al.  Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population , 2020, International journal of vascular medicine.

[9]  David L. Brown,et al.  Association of Inferior Vena Cava Filter Placement for Venous Thromboembolic Disease and a Contraindication to Anticoagulation With 30-Day Mortality , 2018, JAMA network open.

[10]  H. Abdel-Razeq,et al.  Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! , 2018, Thrombosis Journal.

[11]  R. Pesavento,et al.  Are too many inferior vena cava filters used? Controversial evidences in different clinical settings: a narrative review , 2018, Internal and Emergency Medicine.

[12]  H. Krumholz,et al.  Inferior Vena Cava Filters to Prevent Pulmonary Embolism: Systematic Review and Meta-Analysis. , 2017, Journal of the American College of Cardiology.

[13]  K. Hong,et al.  Decreasing Utilization of Inferior Vena Cava Filters in Post-FDA Warning Era: Insights From 2005 to 2014 Nationwide Inpatient Sample. , 2017, Journal of the American College of Radiology : JACR.

[14]  S. Kalva,et al.  Complications of inferior vena cava filters. , 2016, Cardiovascular diagnosis and therapy.

[15]  K. Sniderman,et al.  Temporary inferior vena cava filter indications, retrieval rates, and follow-up management at a multicenter tertiary care institution. , 2016, Journal of Vascular Surgery.

[16]  R. White,et al.  Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. , 2016, Thrombosis research.

[17]  F. Barral,et al.  Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. , 2015, JAMA.

[18]  K. Nugent,et al.  Indications and Appropriateness of Inferior Vena Cava Filter Placement , 2015, The American journal of the medical sciences.

[19]  H. Abdel-Razeq,et al.  Inferior vena cava filters in patients with advanced-stage cancer. , 2014, Hematology/oncology and stem cell therapy.

[20]  M. Crowther,et al.  Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. , 2013, JAMA internal medicine.

[21]  R. Gralla,et al.  Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial , 2012, Supportive Care in Cancer.

[22]  D. Levin,et al.  Placement and removal of inferior vena cava filters: national trends in the medicare population. , 2011, Journal of the American College of Radiology : JACR.

[23]  J. Kline,et al.  Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association , 2011, Circulation.

[24]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[25]  Rebecca Chitima-Matsiga,et al.  Retrievable inferior vena cava filters are not getting retrieved: where is the gap? , 2010, Thrombosis research.

[26]  J. Gore,et al.  A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. , 2010, Archives of internal medicine.

[27]  M. Nazzal,et al.  Complications related to inferior vena cava filters: a single-center experience. , 2010, Annals of vascular surgery.

[28]  A. Maraveyas,et al.  Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer , 2008, Acta oncologica.

[29]  H. Billett,et al.  Efficacy of inferior vena cava filters in anticoagulated patients , 2007, Journal of thrombosis and haemostasis : JTH.

[30]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[31]  L. Bressollette Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism: The PREPIC (Prévention du Risque d’Embolie Pulmonaire par Interruption Cave) Randomized Study , 2005, Circulation.

[32]  H. Büller,et al.  Fondaparinux or enoxaparin for initial treatment of symptomatic deep venous thrombosis: Randomized trial , 2004 .

[33]  K. Ahrar,et al.  Use of inferior vena caval filters and survival in patients with malignancy , 2004, Cancer.

[34]  P. Stein,et al.  Twenty-one-year trends in the use of inferior vena cava filters. , 2004, Archives of internal medicine.

[35]  G. Raskob,et al.  Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis , 2004, Annals of Internal Medicine.

[36]  B. Heniford,et al.  Complications of Inferior Vena Cava Filters , 2003, The American surgeon.

[37]  M. Prins,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[38]  K. Calligaro,et al.  Inferior vena cava filters in malignant disease. , 2002, Journal of vascular surgery.

[39]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[40]  P. Thodiyil,et al.  Variation in Relative Risk of Venous Thromboembolism in Different Cancers , 2002, Thrombosis and Haemostasis.

[41]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  W. O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[43]  L. Greenfield,et al.  Vena caval filters for the prevention of pulmonary embolism. , 1998 .

[44]  F. Barral,et al.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.

[45]  S. Desai,et al.  National trends in utilization of inferior vena cava filters in the United States, 2000-2009. , 2014, Journal of vascular surgery. Venous and lymphatic disorders.

[46]  G. Moneta Placement and Removal of Inferior Vena Cava Filters: National Trends in the Medicare Population , 2012 .

[47]  D. Imberti,et al.  Retrievable vena cava filters: key considerations. , 2008, Thrombosis research.

[48]  F. Barral,et al.  A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. , 2007, Chest.

[49]  Lain,et al.  A CLINICAL TRIAL OF VENA CAVAL FILTERS IN THE PREVENTION OF PULMONARY EMBOLISM IN PATIENTS WITH PROXIMAL DEEP-VEIN THROMBOSIS , 2000 .

[50]  H. Abdel-Razeq,et al.  open access to scientific and medical research Open Access Full Text Article Rapid Communication , 2022 .